Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.